Sifalimumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Sifalimumab
Sifalimumab 4YPG.png
Fab fragment of sifalimumab bound to IFN-α2A. From PDB: 4ypg​.
Monoclonal antibody
Type Whole antibody
Source Human
Target Interferon α
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6518H10008N1724O2032S38
Molar mass 146.25 kg/mol
 ☒N☑Y (what is this?)  (verify)

Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. It targets interferon a.[1]

Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing internal product, anifrolumab, into Phase III trials.[2][3][4]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab" (PDF). American Medical Association. 
  2. ^ "Press release: New Hope for Lupus Patients". MedImmune. 11 August 2015. Archived from the original on 31 July 2017. 
  3. ^ "Sifalimumab". AdisInsight. Retrieved 31 July 2017. 
  4. ^ "Sifalimumab". NHS Specialist Pharmacy Service. Retrieved 31 July 2017.